The Prognostic Role of Baseline Metabolic Tumor Burden and Systemic Inflammation Biomarkers in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Radium-223: A Proof of Concept Study

The Prognostic Role of Baseline Metabolic Tumor Burden and Systemic Inflammation Biomarkers in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Radium-223: A Proof of Concept Study

Over the last years has emerged the urgent need for the identification of reliable prognostic biomarkers able to potentially identify metastatic castration-resistant prostate cancer (mCRPC) patients most likely to benefit from Radium-223 (Ra-223) since baseline. In the present monocentric retrospect...

Full description

Bibliographic Details
Main Authors: Matteo Bauckneht, Sara Elena Rebuzzi, Alessio Signori, Maria Isabella Donegani, Veronica Murianni, Alberto Miceli, Roberto Borea, Stefano Raffa, Alessandra Damassi, Marta Ponzano, Fabio Catalano, Valentino Martelli, Cecilia Marini, Francesco Boccardo, Silvia Morbelli, Gianmario Sambuceti, Giuseppe Fornarini
Format: Article
Language:English
Published: MDPI AG 2020-10-01
Series:Cancers
Subjects:
metastatic castration resistant prostate cancer
radium-223
neutrophil-to-lymphocyte ratio
lymphocyte-to-monocyte ratio
platelet-to-lymphocyte ratio
systemic inflammation index
Online Access:https://www.mdpi.com/2072-6694/12/11/3213

Internet

https://www.mdpi.com/2072-6694/12/11/3213

Similar Items